Joakim EsbjÃ¶rnsson

List of Publications by Year
in descending order

49 papers	1,048 citations	566801 15 h-index	454577 30 g-index
53 all docs	53 docs citations	53 times ranked	1347 citing authors

#	Article	IF	Citations
1	Quantifying rates of HIV-1 flow between risk groups and geographic locations in Kenya: A country-wide phylogenetic study. Virus Evolution, 2022, 8, veac016.	2.2	6
2	Phylogeographic Assessment Reveals Geographic Sources of HIV-1 Dissemination Among Men Who Have Sex With Men in Kenya. Frontiers in Microbiology, 2022, 13, 843330.	1.5	2
3	A Stronger Innate Immune Response During Hyperacute Human Immunodeficiency Virus Type 1 (HIV-1) Infection Is Associated With Acute Retroviral Syndrome. Clinical Infectious Diseases, 2021, 73, 832-841.	2.9	5
4	The Role of Phylogenetics in Discerning HIV-1 Mixing among Vulnerable Populations and Geographic Regions in Sub-Saharan Africa: A Systematic Review. Viruses, 2021, 13, 1174.	1.5	9
5	Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive Paediatric HIV-1 Outbreak in Larkana, Pakistan. Frontiers in Microbiology, 2021, 12, 658186.	1.5	8
6	TRIM22 genotype is not associated with markers of disease progression in children with HIV-1 infection. Aids, 2021, Publish Ahead of Print, 2445-2450.	1.0	0
7	Inverted CD8 T-Cell Exhaustion and Co-Stimulation Marker Balance Differentiate Aviremic HIV-2-Infected From Seronegative Individuals. Frontiers in Immunology, 2021, 12, 744530.	2.2	5
8	The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau. AIDS Research and Therapy, 2020, 17, 33.	0.7	8
9	Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread. Scientific Reports, 2020, 10, 3468.	1.6	14
10	HIV-1 Transmission Patterns Within and Between Risk Groups in Coastal Kenya. Scientific Reports, 2020, 10, 6775.	1.6	13
11	HIV-2 as a model to identify a functional HIV cure. AIDS Research and Therapy, 2019, 16, 24.	0.7	24
12	New insights are game-changers in HIV-2 disease management â€“ Authors' reply. Lancet HIV,the, 2019, 6, e214-e215.	2.1	4
13	Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoproteinâ€“Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2â€“Infected Individuals. Journal of Infectious Diseases, 2019, 219, 1749-1754.	1.9	7
14	T-cell and B-cell perturbations are similar in ART-naive HIV-1 and HIV-1/2 dually infected patients. Aids, 2019, 33, 1143-1153.	1.0	6
15	Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV,the, 2019, 6, e25-e31.	2.1	57
16	Low Postseroconversion CD4 + T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection. MBio, 2019, 10, .	1.8	7
17	Low-Bias RNA Sequencing of the HIV-2 Genome from Blood Plasma. Journal of Virology, 2019, 93, .	1.5	11
18	Analysis of HIV-1 envelope evolution suggests antibody-mediated selection of common epitopes among Chinese former plasma donors from a narrow-source outbreak. Scientific Reports, 2018, 8, 5743.	1.6	3

#	Article	IF	Citations
19	Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. Aids, 2018, 32, 877-884.	1.0	9
20	HIV-1 subtype diversity, transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya. PLoS ONE, 2018, 13, e0206177.	1.1	13
21	Evolutionary analysis of the Chikungunya virus epidemic in Mexico reveals intra-host mutational hotspots in the E1 protein. PLoS ONE, 2018, 13, e0209292.	1.1	8
22	Prevalence of HIV-1 pretreatment drug resistance among treatment naÃ¯ve pregnant women in Bissau, Guinea Bissau. PLoS ONE, 2018, 13, e0206406.	1.1	11
23	Molecular epidemiology of HIV-1 in Iceland: Early introductions, transmission dynamics and recent outbreaks among injection drug users. Infection, Genetics and Evolution, 2017, 49, 157-163.	1.0	19
24	Defining HIV-1 transmission clusters based on sequence data. Aids, 2017, 31, 1211-1222.	1.0	131
25	Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North Africa. Heliyon, 2017, 3, e00352.	1.4	11
26	Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996â€“2012. Infection Ecology and Epidemiology, 2017, 7, 1328964.	0.5	6
27	Differential effects of sex in a West African cohort of HIVâ€1, HIVâ€2 and HIVâ€1/2 dually infected patients: men are worse off. Tropical Medicine and International Health, 2016, 21, 253-262.	1.0	16
28	Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e79-e82.	0.9	2
29	Molecular characterization of HCV in a Swedish county over 8 years (2002â€“2009) reveals distinct transmission patterns. Infection Ecology and Epidemiology, 2016, 6, 30670.	0.5	3
30	Viral Evolution and Cytotoxic T Cell Restricted Selection in Acute Infant HIV-1 Infection. Scientific Reports, 2016, 6, 29536.	1.6	13
31	HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. Virus Evolution, 2016, 2, vew010.	2.2	68
32	Cocirculation of Several Similar But Unique HIV-1 Recombinant Forms in Guinea-Bissau Revealed by Near Full-Length Genomic Sequencing. AIDS Research and Human Retroviruses, 2015, 31, 938-945.	0.5	3
33	Effect of HIV-2 infection on HIV-1 disease progression and mortality. Aids, 2014, 28, 614-615.	1.0	13
34	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-957.	1.0	32
35	The origin and emergence of an HIV-1 epidemic. Aids, 2014, 28, 1031-1040.	1.0	13
36	Faster Progression to AIDS and AIDS-Related Death Among Seroincident Individuals Infected With Recombinant HIV-1 A3/CRF02_AG Compared With Sub-subtype A3. Journal of Infectious Diseases, 2014, 209, 721-728.	1.9	33

#	Article	IF	Citations
37	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-57.	1.0	9
38	High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. Infection, Genetics and Evolution, 2013, 19, 369-377.	1.0	18
39	Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Human Vaccines and Immunotherapeutics, 2013, 9, 2103-2110.	1.4	3
40	Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1. Journal of Virology, 2012, 86, 961-971.	1.5	39
41	Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection. New England Journal of Medicine, 2012, 367, 224-232.	13.9	94
42	Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. Aids, 2012, 26, 1739-1744.	1.0	3
43	HIV-1 Molecular Epidemiology in Guinea-Bissau, West Africa: Origin, Demography and Migrations. PLoS ONE, 2011, 6, e17025.	1.1	55
44	Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries. Apmis, 2011, 119, 487-497.	0.9	8
45	Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	39
46	Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa. Retrovirology, 2010, 7, 23.	0.9	80
47	Frequent Intrapatient Recombination between Human Immunodeficiency Virus Type 1 R5 and X4 Envelopes: Implications for Coreceptor Switch. Journal of Virology, 2007, 81, 3369-3376.	1.5	48
48	Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. Journal of General Virology, 2005, 86, 2859-2869.	1.3	56
49	Interferon Alpha-Inducible Protein 27 Expression Is Linked to Disease Severity in Chronic Infection of Both HIV-1 and HIV-2. Frontiers in Virology, 0, 2, .	0.7	3